KEW

KEW, Inc., established in 2009 and headquartered in Cambridge, Massachusetts, specializes in genomic testing services for cancer patients. The company's core offering, CANCERPLEX, is a precision medicine service that analyzes a patient's genetic drivers to help oncologists select personalized, targeted therapies. KEW's suite of products includes CANCERPLEX FP, a full panel test with immunotherapy options, CANCERPLEX TS for common tumor sites, and CANCERPLEX TX for FDA-approved targeted therapies. The company delivers these solutions through strategic partnerships and distributors, enabling evidence-driven treatment decisions in cancer care.